Zacks: Analysts Expect MedEquities Realty Trust (MRT) to Announce $0.30 EPS

Equities analysts expect MedEquities Realty Trust (NYSE:MRT) to post earnings of $0.30 per share for the current fiscal quarter, Zacks reports. Two analysts have provided estimates for MedEquities Realty Trust’s earnings, with the lowest EPS estimate coming in at $0.29 and the highest estimate coming in at $0.31. MedEquities Realty Trust reported earnings of $0.27 per share during the same quarter last year, which suggests a positive year over year growth rate of 11.1%. The business is scheduled to report its next earnings results on Tuesday, August 14th.

On average, analysts expect that MedEquities Realty Trust will report full year earnings of $1.20 per share for the current financial year, with EPS estimates ranging from $1.19 to $1.22. For the next fiscal year, analysts forecast that the company will report earnings of $1.24 per share, with EPS estimates ranging from $1.22 to $1.27. Zacks’ earnings per share calculations are an average based on a survey of research analysts that that provide coverage for MedEquities Realty Trust.

Get MedEquities Realty Trust alerts:

MedEquities Realty Trust (NYSE:MRT) last announced its quarterly earnings data on Thursday, May 10th. The financial services provider reported $0.16 EPS for the quarter, missing the Zacks’ consensus estimate of $0.30 by ($0.14). MedEquities Realty Trust had a net margin of 34.63% and a return on equity of 6.17%. The firm had revenue of $16.72 million during the quarter, compared to analysts’ expectations of $16.41 million.

A number of brokerages have commented on MRT. B. Riley set a $13.00 price objective on shares of MedEquities Realty Trust and gave the company a “buy” rating in a research report on Monday. KeyCorp dropped their price objective on shares of MedEquities Realty Trust from $13.00 to $12.00 and set an “overweight” rating on the stock in a research report on Monday, April 16th. ValuEngine downgraded shares of MedEquities Realty Trust from a “hold” rating to a “sell” rating in a research report on Wednesday, May 2nd. Cantor Fitzgerald reissued a “buy” rating and issued a $14.00 price objective on shares of MedEquities Realty Trust in a research report on Wednesday, February 21st. Finally, Citigroup lowered their target price on shares of MedEquities Realty Trust from $12.00 to $10.00 and set a “neutral” rating for the company in a report on Thursday, March 1st. One equities research analyst has rated the stock with a sell rating, three have assigned a hold rating and four have assigned a buy rating to the company. The stock has an average rating of “Hold” and an average price target of $12.43.

Shares of NYSE:MRT traded up $0.07 during trading hours on Friday, reaching $10.39. The stock had a trading volume of 126,255 shares, compared to its average volume of 156,942. MedEquities Realty Trust has a 1 year low of $10.27 and a 1 year high of $10.43. The company has a market cap of $326.84 million, a PE ratio of 9.11 and a beta of -0.18.

The business also recently announced a quarterly dividend, which will be paid on Tuesday, June 5th. Stockholders of record on Tuesday, May 22nd will be issued a $0.21 dividend. This represents a $0.84 annualized dividend and a dividend yield of 8.08%. The ex-dividend date of this dividend is Monday, May 21st. MedEquities Realty Trust’s payout ratio is 73.68%.

In other news, Director Bluemountain Capital Managemen sold 17,674 shares of the company’s stock in a transaction on Friday, May 4th. The shares were sold at an average price of $10.16, for a total value of $179,567.84. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. In the last 90 days, insiders sold 235,786 shares of company stock valued at $2,435,627. Company insiders own 2.50% of the company’s stock.

Several institutional investors have recently modified their holdings of the company. American Century Companies Inc. boosted its stake in MedEquities Realty Trust by 22.3% during the 4th quarter. American Century Companies Inc. now owns 2,111,333 shares of the financial services provider’s stock worth $23,689,000 after purchasing an additional 385,125 shares during the period. BlackRock Inc. boosted its stake in MedEquities Realty Trust by 2.3% during the 4th quarter. BlackRock Inc. now owns 1,424,525 shares of the financial services provider’s stock worth $15,984,000 after purchasing an additional 32,289 shares during the period. Russell Investments Group Ltd. boosted its stake in MedEquities Realty Trust by 10.8% during the 1st quarter. Russell Investments Group Ltd. now owns 1,165,213 shares of the financial services provider’s stock worth $12,246,000 after purchasing an additional 113,799 shares during the period. Northpointe Capital LLC boosted its stake in MedEquities Realty Trust by 1.6% during the 4th quarter. Northpointe Capital LLC now owns 863,411 shares of the financial services provider’s stock worth $9,687,000 after purchasing an additional 13,444 shares during the period. Finally, Schwab Charles Investment Management Inc. boosted its stake in MedEquities Realty Trust by 69.2% during the 4th quarter. Schwab Charles Investment Management Inc. now owns 776,946 shares of the financial services provider’s stock worth $8,718,000 after purchasing an additional 317,829 shares during the period. Institutional investors and hedge funds own 89.09% of the company’s stock.

MedEquities Realty Trust Company Profile

MedEquities Realty Trust (NYSE: MRT) is a self-managed and self-administered real estate investment trust that invests in a diversified mix of healthcare properties and healthcare-related real estate debt investments. The Company's management team has extensive industry experience in acquiring, owning, developing, financing, operating, leasing and monetizing many types of healthcare properties and portfolios.

Get a free copy of the Zacks research report on MedEquities Realty Trust (MRT)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for MedEquities Realty Trust (NYSE:MRT)